Forbion

NorthSea Therapeutics Completes US$80 Million Series C Fundraising to Advance Clinical Programs in Metabolic Disorders

Retrieved on: 
Friday, December 17, 2021
Other Professional Services, Biotechnology, Pharmaceutical, Finance, Health, Hospitals, Professional Services, Clinical Trials, NASH, Icosabutate, NorthSea Therapeutics, Ysios Capital, Forbion, NASH, ICOSABUTATE, NORTHSEA THERAPEUTICS, YSIOS CAPITAL, FORBION

NorthSea Therapeutics B.V., (NST) a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, today announces the close of a USD 80 million Series C financing round.

Key Points: 
  • NorthSea Therapeutics B.V., (NST) a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, today announces the close of a USD 80 million Series C financing round.
  • Interim results showed a rapid and significant reduction of biomarkers in liver injury, inflammation, and fibrosis in biopsy-confirmed NASH patients.
  • In addition, treatment with Icosabutate showed a favorable safety and tolerability profile and additional improvements in atherogenic lipids and glycemic control.
  • NorthSea Therapeutics B.V.(NST) is a Dutch biotech company focused on developing structurally engineered fatty acids (SEFAs) for the treatment of NASH and other metabolic disorders.

Rectify Pharmaceuticals Launches with $100 Million Series A Financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund

Retrieved on: 
Thursday, October 14, 2021
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Scripps Research, The Programme, Degenerative disease, Disease, POC, Partner, Gastrointestinal tract, Therapy, Medication, Pharma, EIF, DVI, Marshall Plan, Precision medicine, Health, Patient, ERP, Biotechnology, Computational biology, Partner (business rank), ABC, BGV, Drug discovery, Alnylam Pharmaceuticals, EUR, Vertex Pharmaceuticals, European Recovery Plan, Liver, Senior, Socially responsible investing, CBO, Department, PFM Group, Eye, Investment, Executive, Central nervous system, Vertex, CFTR, Growth, Atlas, Atlas Venture, EFSI, LFA, Cystic fibrosis, Lists of diseases, Institute of Liver and Biliary Sciences, Company, Omega, Entrepreneurship, United Nations Principles of Medical Ethics, Pharmaceutical industry, Management, Aquaculture, Fine chemical, Rectify Pharmaceuticals, Inc. (“Rectify”), Atlas Venture, Omega Funds, Forbion, Longwood Fund, RECTIFY PHARMACEUTICALS, INC. (“RECTIFY”), ATLAS VENTURE, OMEGA FUNDS, FORBION, LONGWOOD FUND

Rectify Pharmaceuticals, Inc. , (Rectify) a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics that restore ABC transporter function, today announced it has closed a $100 million Series A financing co-led by Atlas Venture, Omega Funds, Forbion, and Longwood Fund.

Key Points: 
  • Rectify Pharmaceuticals, Inc. , (Rectify) a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics that restore ABC transporter function, today announced it has closed a $100 million Series A financing co-led by Atlas Venture, Omega Funds, Forbion, and Longwood Fund.
  • Rectify plans to use this financing to fund the company through its first human proof-of-concept (POC) studies.
  • We founded Rectify to deliver life-changing therapies to patients with serious genetic diseases, said Rajesh Devraj, Ph.D., President and Chief Executive Officer and venture partner with Atlas Venture.
  • Jonathan Moore, Ph.D., Chief Scientific Officer, founded Rectify with Atlas Venture in 2020.

Forbion invests USD 2.3M in seed financing of CoviCept Therapeutics, Inc.

Retrieved on: 
Tuesday, January 19, 2021
Medical devices, Infectious diseases, Finance, Clinical trials, Professional services, Biotechnology, Health, Pharmaceutical, Other Professional Services, Given names, Jeffrey Esko, van Deventer, Esko, Benelux, Sander, Europe, Economy, Forbion, CoviCept Therapeutics, Inc.

CoviCept was founded by Sam Tsimikas, Philip Gordts and Jeffrey Esko, all from the University of California San Diego.

Key Points: 
  • CoviCept was founded by Sam Tsimikas, Philip Gordts and Jeffrey Esko, all from the University of California San Diego.
  • Sander van Deventer, Operating Partner of Forbion, added: Our investment in CoviCept is an example of Forbions commitment to responsible drug development.
  • The board of directors of CoviCept will comprise Sam Tsimikas, Philip Gordts, Jeffrey Esko and Sander van Deventer (Forbion).
  • Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany.

DGAP-News: CatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for checkpoint-inhibitor refractory patients

Retrieved on: 
Tuesday, November 10, 2020
Clinical medicine, Clusters of differentiation, Medicine, Cancer immunotherapy, Immune system, Medical specialties, Immunotherapy, Virotherapy, Programmed cell death protein 1, PD-L1, CTL, GDF-15, CTL-002, CatalYm, Vesalius Biocapital III, Forbion, BioGeneration Ventures (BGV), Novartis Venture Fund (NVF), Wachstumsfonds Bayern, coparion

Munich, Germany, November 10, 2020 - CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the closing of its EUR50 million Series B financing round.

Key Points: 
  • Munich, Germany, November 10, 2020 - CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the closing of its EUR50 million Series B financing round.
  • CTL-002 will be developed as a monotherapy and in combination with approved PD-1/PD-L1 antagonists in checkpoint-blocker refractory patients.
  • The company's lead product candidate CTL-002, a neutralizing GDF-15 antibody, is set to enter clinical development in H2 2020.
  • The fund invests up to EUR 10 million per company, usually in several financing rounds of EUR 1-5 million each.

Forbion Portfolio Company, Enterprise Therapeutics’ First-in-Class TMEM16A Potentiator Program for Treatment of Cystic Fibrosis and Other Respiratory Diseases Acquired by Roche

Retrieved on: 
Wednesday, October 7, 2020
Science, Biotechnology, Research, Pharmaceutical, Finance, Health, Professional services, Clinical trials, Anatomy, Organ systems, Branches of biology, RTT, Channelopathies, Cystic fibrosis, Mucus, Ivacaftor, Forbion, Enterprise Therapeutics, Cystic Fibrosis (CF)

The TMEM16A portfolio is focused toward treating all people with cystic fibrosis (CF), with potential to benefit people with other severe respiratory diseases characterised by excessive mucus congestion.

Key Points: 
  • The TMEM16A portfolio is focused toward treating all people with cystic fibrosis (CF), with potential to benefit people with other severe respiratory diseases characterised by excessive mucus congestion.
  • Dr John Ford, CEO, Enterprise Therapeutics, said: Roche and Genentech have a proven track record of bringing new medicines to people with respiratory diseases, and have recognised the opportunity that our TMEM16A potentiator portfolio presents.
  • TMEM16A potentiation has the potential to significantly increase the quality of life for people living with cystic fibrosis, for many of whom existing therapies are not effective.
  • We are delighted that Roche after its acquisition of Forbions portfolio company Promedior has decided to acquire Enterprises TMEM16A potentiator program, adding yet another exciting program to their respiratory portfolio.

Inversago Pharma Closes US$35M Series B Financing Round and Expands Board of Directors

Retrieved on: 
Tuesday, September 8, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Incerti, Inversago Pharma, Forbion, the Fonds de solidarité FTQ

Todays financing is a recognition of the progress achieved over the past two years by our team, said Franois Ravenelle, PhD, CEO and founder of Inversago Pharma.

Key Points: 
  • Todays financing is a recognition of the progress achieved over the past two years by our team, said Franois Ravenelle, PhD, CEO and founder of Inversago Pharma.
  • We are privileged to have secured the financing from a transatlantic syndicate of leading and committed investors like Forbion and the Fonds de solidarit FTQ.
  • In conjunction with this financing, Inversago appointed Carlo Incerti, MD, an Operating Partner at Forbion, as Chairman of the board of directors, Marco Boorsma, PhD, a General Partner at Forbion, and Patricia Allen, a biotech leader, as directors of the Company.
  • I am delighted to join Inversago when the Company is transitioning from the pre-clinical stage to the first human trials, said Carlo Incerti, MD, Chairman of the board of directors.

Inversago Pharma Closes US$35M Series B Financing Round and Expands Board of Directors

Retrieved on: 
Tuesday, September 8, 2020
Health, Technology, Other Technology, Software, Clinical trials, Pharmaceutical, Biotechnology, Incerti, Inversago Pharma, Forbion, the Fonds de solidarité FTQ

Todays financing is a recognition of the progress achieved over the past two years by our team, said Franois Ravenelle, PhD, CEO and founder of Inversago Pharma.

Key Points: 
  • Todays financing is a recognition of the progress achieved over the past two years by our team, said Franois Ravenelle, PhD, CEO and founder of Inversago Pharma.
  • We are privileged to have secured the financing from a transatlantic syndicate of leading and committed investors like Forbion and the Fonds de solidarit FTQ.
  • In conjunction with this financing, Inversago appointed Carlo Incerti, MD, an Operating Partner at Forbion, as Chairman of the board of directors, Marco Boorsma, PhD, a General Partner at Forbion, and Patricia Allen, a biotech leader, as directors of the Company.
  • I am delighted to join Inversago when the Company is transitioning from the pre-clinical stage to the first human trials, said Carlo Incerti, MD, Chairman of the board of directors.

Forbion Portfolio Company, KaNDy Therapeutics, to Be Acquired by Bayer

Retrieved on: 
Tuesday, August 11, 2020
Professional services, Health, Other Health, Finance, Pharmaceutical, Biotechnology, Companies, Industries, Aspirin, Bayer, IG Farben, Leverkusen, Goldman Sachs, Business, Kandy, Forbion, Bayer, KaNDy Therapeutics, NT-814

We are delighted that Bayer has decided to acquire KaNDy and support the ongoing work around the symptoms of menopause.

Key Points: 
  • We are delighted that Bayer has decided to acquire KaNDy and support the ongoing work around the symptoms of menopause.
  • Bayer has been our preferred partner due to its leading position in the area of womens healthcare, said Dr. Mary Kerr, Co-Founder and CEO of KaNDy Therapeutics.
  • Goldman Sachs International is serving as financial advisor to KaNDy Therapeutics Ltd., while Goodwin is serving as legal counsel.
  • Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world.

Azafaros Completes EUR 25 Million Series A Financing to Advance Rare Metabolic Disorders Pipeline

Retrieved on: 
Thursday, February 6, 2020
University, Biotechnology, Education, Professional services, Health, Pharmaceutical, Research, Genetics, Science, Clinical trials, Finance, Endocrinology, Metabolic disorder, Metabolism, Azafaros, Lysosomal Storage Disorders, Forbion, BGV, BioMedPartners

Azafaros B.V. announced today the successful closing of its Series A financing round raising EUR 25 million (approximately USD 28 million).

Key Points: 
  • Azafaros B.V. announced today the successful closing of its Series A financing round raising EUR 25 million (approximately USD 28 million).
  • It allows us to build our organization and expand our executive team with passionate and experienced people and to advance our rare metabolic disorders pipeline, commented Olivier Morand, Chief Executive Officer at Azafaros.
  • Professor Hans Aerts stated: Azafaros has secured the capital to develop a pipeline of first-in-class small molecules that have great potential for treating patients with rare diseases.
  • Azafaros was founded in 2018 by a team of experienced industry professionals and scientists aspiring to address rare genetic metabolic disorders through a pipeline of oral small molecules with disease-modifying potential.

NorthSea Therapeutics Announces US $40 Million Series B Financing to Complete Phase IIb ICONA study in NASH and to Advance Two Additional SEFAs into the Clinic

Retrieved on: 
Wednesday, January 8, 2020
Biotechnology, General Health, Health, Pharmaceutical, Oncology, HIV/AIDS, NorthSea Therapeutics, venBio Partners, Sofinnova Investments, Forbion, New Science Ventures, Novo Holdings A/S and Novo Seeds, BioGeneration Ventures (BGV)

The Company will develop two additional SEFAs within its clinical pipeline in addition to completing the Phase 2b with its lead candidate Icosabutate.

Key Points: 
  • The Company will develop two additional SEFAs within its clinical pipeline in addition to completing the Phase 2b with its lead candidate Icosabutate.
  • The Company aims to initiate a Phase 1 study in the second half of 2020.
  • This financing will enable NST to complete its ongoing Phase 2b trial in NASH before the vast majority of NASH assets currently in clinical development.
  • A Phase 2b study was initiated in July 2019 (ICONA) to study the efficacy of icosabutate in NASH.